BridgeBio says Phase 3 FORTIFY data show BBP-418 normalizes HS troponin I in LGMD2I/R9 patients by Month 12

PUBT · 3d ago
BridgeBio says Phase 3 FORTIFY data show BBP-418 normalizes HS troponin I in LGMD2I/R9 patients by Month 12
  • BridgeBio presented new 12-month exploratory cardiac data from its Phase 3 FORTIFY trial of BBP-418 in LGMD2I/R9.
  • Results indicated improvements in heart-injury blood markers, with more patients returning to normal ranges than on placebo.
  • More treated patients showed stable or improved heart pumping function versus placebo, supporting a potential disease-modifying profile.
  • BBP-418 is under FDA Priority Review, with a PDUFA target action date of November 27, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050730PRIMZONEFULLFEED9839250) on October 05, 2026, and is solely responsible for the information contained therein.